{"id":569938,"date":"2025-12-01T00:47:15","date_gmt":"2025-12-01T00:47:15","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/569938\/"},"modified":"2025-12-01T00:47:15","modified_gmt":"2025-12-01T00:47:15","slug":"les-specialistes-fixent-un-cadre-precis","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/569938\/","title":{"rendered":"les sp\u00e9cialistes fixent un cadre pr\u00e9cis"},"content":{"rendered":"<p>                     <img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.europesays.com\/fr\/wp-content\/uploads\/2025\/12\/1595262_upload-1-si2lqaionneu-sipa-sipahub60033598-000052.jpg\" alt=\"Programme de traitement de l\u2019ob\u00e9sit\u00e9, dans un h\u00f4pital de Leipzig (Allemagne), le 6\u00a0juin\u00a02025.\"   width=\"664\" height=\"443\"\/>    Programme de traitement de l\u2019ob\u00e9sit\u00e9, dans un h\u00f4pital de Leipzig (Allemagne), le 6\u00a0juin\u00a02025.  JAN WOITAS\/DPA\/SIPA                 <\/p>\n<p class=\"article__paragraph  \">L\u2019arriv\u00e9e r\u00e9cente des traitements m\u00e9dicamenteux de l\u2019ob\u00e9sit\u00e9 (TMO) a chang\u00e9 la donne dans la prise en charge de cette maladie multifactorielle. Le Groupe de concertation et de coordination des centres sp\u00e9cialis\u00e9s de l\u2019ob\u00e9sit\u00e9 (GCC-CSO) et le r\u00e9seau fran\u00e7ais de recherche clinique sur l\u2019ob\u00e9sit\u00e9 et les maladies m\u00e9taboliques Force <a href=\"https:\/\/www.obesitefrance.fr\/actualites\/prise-de-position-nationale-sur-les-traitements-medicamenteux-de-lobesite-et-leur-accompagnement-en-pratique\" target=\"_blank\" rel=\"noopener\" title=\"Nouvelle fen\u00eatre\">ont publi\u00e9, mardi 25\u00a0novembre, des recommandations<\/a> visant \u00e0 pr\u00e9ciser le r\u00f4le de ces mol\u00e9cules dans le parcours de soins.<\/p>\n<p>                                   Lire aussi |  Article r\u00e9serv\u00e9 \u00e0 nos abonn\u00e9s  <a href=\"https:\/\/www.lemonde.fr\/societe\/article\/2025\/08\/22\/wegovy-mounjaro-les-medicaments-antiobesite-debarquent-chez-les-medecins-generalistes_6633343_3224.html\" class=\"js-article-read-also catcher--favoris__link\" data-premium=\"1\" id=\"article-title-3434834\" target=\"_blank\" rel=\"noopener\">Wegovy, Mounjaro\u2026\u00a0: les m\u00e9dicaments antiob\u00e9sit\u00e9 arrivent chez les m\u00e9decins g\u00e9n\u00e9ralistes<\/a>    <\/p>\n<p>   Lire plus tard  <\/p>\n<p class=\"article__paragraph  \">Trois analogues du GLP-1 (pour Hormone Glucagon-Like Peptide-1) sont disponibles en France et ont \u00e9t\u00e9 \u00e9tudi\u00e9s\u00a0: le s\u00e9maglutide (Wegovy, du laboratoire danois Novo Nordisk), le tirz\u00e9patide (Mounjaro, de l\u2019am\u00e9ricain Lilly), commercialis\u00e9s depuis octobre\u00a02024, et le liraglutide (Saxenda, de Novo Nordisk), autoris\u00e9 en France depuis 2021. Ces m\u00e9dicaments injectables peuvent \u00eatre, depuis le 23\u00a0juin, prescrits par les m\u00e9decins g\u00e9n\u00e9ralistes. Leur acc\u00e8s \u00e9tait auparavant r\u00e9serv\u00e9 \u00e0 des sp\u00e9cialistes.<\/p>\n<p class=\"article__paragraph  \">\u00ab\u00a0C\u2019est l\u2019ouverture \u00e0 tous les m\u00e9decins qui nous a pouss\u00e9s \u00e0 acc\u00e9l\u00e9rer notre prise de position pour r\u00e9pondre aux questions\u00a0: pour qui, pendant combien de temps, quelle pr\u00e9caution d\u2019emploi, quels conseils donner aux patients mais aussi aux professionnels de sant\u00e9\u2026\u00a0?\u00a0\u00bb, r\u00e9sume Emmanuel Disse, chef du service endocrinologie, diab\u00e8te, nutrition, aux Hospices civils de Lyon, coordinateur de ce travail.<\/p>\n<p class=\"reading-mode-only \"><strong>Il vous reste 76.5% de cet article \u00e0 lire. La suite est r\u00e9serv\u00e9e aux abonn\u00e9s.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"Programme de traitement de l\u2019ob\u00e9sit\u00e9, dans un h\u00f4pital de Leipzig (Allemagne), le 6\u00a0juin\u00a02025. JAN WOITAS\/DPA\/SIPA L\u2019arriv\u00e9e r\u00e9cente des&hellip;\n","protected":false},"author":2,"featured_media":569939,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[1011,27,72,71],"class_list":{"0":"post-569938","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-fr","9":"tag-france","10":"tag-health","11":"tag-sante"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115641559213263743","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/569938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=569938"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/569938\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/569939"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=569938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=569938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=569938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}